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Abstract
Background: Headache disorders are among the most prevalent and burdensome global public-health problems.
Within countries, health policy depends upon knowledge of health within the local populations, but the South-East
Asia Region (SEAR), among WHO’s six world regions, is the only one for which no national headache prevalence
data are available.
Methods: In a cross-sectional population-based study, adults representative of the Nepali-speaking population aged
18–65 years and living in Nepal were randomly recruited using stratified multistage cluster sampling. They were
visited unannounced at home by trained interviewers who used a culturally-adapted Nepali translation of the
structured Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation (HARDSHIP)
questionnaire.
Results: There were 2,100 participants (1,239 females [59.0 %], 861 males [41.0 %]; mean age 36.4 ± 12.8 years) with
9 refusals (participation rate 99.6 %). Over half (1,100; 52.4 %) were resident above 1,000 m and almost one quarter
(470; 22.4 %) lived at or above 2,000 m. The 1-year prevalence of any headache was 85.4 ± 1.5 % (gender- and
age-adjusted 84.9 %), of migraine 34.7 ± 2.0 % (34.1 %), of tension-type headache (TTH) 41.1 ± 2.1 % (41.5 %), of
headache on ≥15 days/month 7.7 ± 1.1 % (7.4 %) and of probable medication-overuse headache (pMOH)
2.2 ± 0.63 % (2.1 %).
There was a strong association between migraine and living at altitude ≥1,000 m (AOR = 1.6 [95 % CI: 1.3-2.0];
p < 0.001). There was a less strong association between TTH and urban dwelling (AOR = 1.3 [95 % CI: 1.1-1.6];
p = 0.003), and a possibly artefactual negative association between TTH and living above 1,000 m (AOR = 0.7
[95 % CI: 0.6-0.8]; p < 0.001).
Conclusion: Headache disorders are very common in Nepal. Migraine is unusually so, and strongly associated with
living at altitude, which in very large part accounts for the high national prevalence: the age- and gender-
standardised prevalence in the low-lying Terai is 27.9 %. Headache occurring on ≥15 days/month is also common.
This new evidence will inform national health policy and provide a basis for health-care needs assessment.
However, research is needed to explain the association between migraine and altitude, since it may be relevant to
health-care interventions.
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Background
Headache disorders are among the most prevalent,
burdensome and costly diseases in the world [1]. The
primary headache disorders, mostly migraine and
tension-type headache (TTH), are of importance to
global public health because they lead to widespread
ill health and impaired quality of life [2], and import-
ant to global economies because they also cause
much loss of productivity [3]. Improper treatment of
migraine or TTH can lead to medication-overuse
headache (MOH), an aggravated disorder which, by
definition, occurs on ≥15 days/month and is a major
additional contributor to global disability. The Global
Burden of Disease Study 2013 (GBD2013) found mi-
graine to be the sixth highest cause of disability
worldwide and MOH the 18th in terms of years of life
lost to disability (YLDs) [4]. Collectively, headache
disorders rank third [5].
Headache prevalence is poorly described in many large
and populous regions of the world. Nowhere is this
more obvious than in the South-East Asia Region
(SEAR), the only one of the World Health Organization’s
six world regions for which no nationwide data have yet
been gathered about the prevalence of headache disor-
ders or their impact on society [6].
Within SEAR, Nepal is one of the poorest countries
[7]. Its population is approximately 30 million [8], of
whom about one quarter live below the international
poverty line and among the others the distribution of
wealth is rather unequal [7]. Furthermore, Nepal is a
country of wide diversity. More than 70 ethnic groups
maintain different cultures and spoken languages [9].
Topographically the country is divided into three physio-
graphic divisions – Terai, Hill and Mountain [10] – rising
from some 60 m above sea level to the Himalayas, includ-
ing Mount Everest, the highest peak on Earth at 8,848 m
[7], to attest Nepal’s extraordinary geographical variation.
Although headache has been found to be one of the
most common complaints among patients in primary
health-care centres in Nepal [11, 12], no epidemiological
studies have established the prevalence of headache dis-
orders in this country. Epidemiological data are required
to inform policy and decide the efficient allocation of
resources in a country such as Nepal which has a very
limited health-care budget. With this purpose, the aim
of our study was two-fold: 1) to estimate the prevalence
of headache disorders of public-health importance: mi-
graine, TTH and MOH; and 2) to explore demographic
and environmental factors associated with these head-
ache disorders in Nepal. The study was conducted as a
project within the Global Campaign against Headache,
which is led by Lifting The Burden (LTB), a UK-registered
non-governmental organisation in official relationship
with the World Health Organization.
Methods
Ethics
The Nepal Health Research Council, the Institutional
Review Committee of Kathmandu University School of
Medical Sciences, Dhulikhel Hospital (IRC-KUSMS) and
the Regional Committee for Health and Research Ethics
in central Norway all approved the study protocol.
All participants were informed about the nature and
purpose of the study. Written consent was obtained by
signature or fingerprint in accordance with requirements
of IRC-KUSMS.
Study design
This was a cross-sectional, population-based survey
using structured interviews administered by trained
health workers making unannounced door-to-door visits
to households in May, 2013. We randomly selected one
eligible adult (aged 18–65 years, Nepali-speaking and liv-
ing in Nepal) from each household. To ensure adequate
representation from the country as a whole, we used
multistage stratified cluster sampling, including all three
physiographic divisions and, within each, all five devel-
opment regions (Far-Western, Midwestern, Western,
Central and Eastern). The details of the sampling and
data collection procedure, including the steps taken to
ensure a very high participation rate, have been pub-
lished elsewhere [10]. The sample size (N = 2,100) was
estimated assuming a headache-type prevalence of
≥10 % and absolute margin of error of 1.3 % with 95 %
confidence interval (CI).
Instruments
We used the Headache-Attributed Restriction, Disability,
Social Handicap and Impaired Participation (HARDSHIP)
questionnaire developed by LTB for similar studies [13].
The English version was translated into Nepalese
according to LTB’s translation protocol for lay docu-
ments [14] and adapted to fit the characteristics of the
Nepalese culture [15].
The full questionnaire has been published previously
[10]. It consisted of five parts. For all participants there
were (i) personal and demographic enquiry and (ii) a
headache screening question (“Have you had a headache
in the last year?”). Those who answered “no” were classi-
fied as headache-free. Those who answered “yes” were
asked whether their headaches were of one or more
types and, if more than one, to focus only on the most
bothersome type. Only those who answered positively to
the screening question were also asked (iii) diagnostic
and (iv) burden and health-care questions relating to
their headache. To the standard HARDSHIP questions
we added others relating to use of herbal therapies. Fi-
nally, there were (v) questions on certain comorbidities
asked of all participants [10].
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We used culturally-validated Nepali-translations of the
Hospital Anxiety and Depression Scale (HADS) [16] and
the Eysenck Personality Questionnaire Neuroticism
Short Form Revised version (EPQRS-N) [17] to assess
psychiatric comorbidity. We measured height, weight
and waist-circumference, and calculated body-mass
index (BMI). We measured blood pressure (BP) using a
digital device (3BM1-3® by Microlife).
We recorded the altitude of each household using a
portable altimeter (SAL 7030® by Sunoh).
Headache diagnosis
Diagnoses were not made during the interviews but later
by an algorithm [13]. Participants reporting headache on
≥15 days/month were first separated as a distinct group
because they cannot be fully diagnosed by questionnaire.
Those who were also overusing acute medication were
considered to have probable MOH (pMOH); the re-
mainder were diagnosed as “other headache on
≥15 days/month”. Medication overuse was diagnosed
in those who: a) reported the use on ≥15 days/month
of either a single class of analgesics, or one type of
herbal medicine, as acute headache treatment; or b) re-
ported using on ≥10 days/month (i) a combination of
analgesics of different classes, or (ii) more than one
type of herbal medicine, or (iii) a combination of anal-
gesics and herbal medicines. Triptans and ergots were
not used.
To all others, reporting headache on ≤14 days/
month, the algorithm applied modified criteria of the
International Classification of Headache Disorders
(ICHD-3 beta) [18] in the following order: definite mi-
graine, definite TTH, probable migraine and probable
TTH. We found that two additional adaptations were
necessary. Firstly, photophobia was reported in associ-
ation with more than three-quarters (75.8 %) of all
headaches and therefore offered little discriminative
value diagnostically. Accordingly, we ignored it when
diagnosing headache types. Secondly, according to
ICHD-3 beta [18], attacks lasting <4 h when untreated
in adults may be compatible with a diagnosis of prob-
able migraine when other criteria are met. Many of our
participants could report attack durations only after
taking acute medication, and some were very short.
We decided to disallow a diagnosis of probable migraine
(in favour of probable TTH) whenever headache duration
was <1 h. We took the view that so short a duration, even
with acute treatment, was very unlikely to be migraine,
given that the adult participant was asked to describe a
“usual” attack [19].
Cases of definite and probable migraine were combined
as, likewise, were cases of definite and probable TTH in
the estimations of prevalence and in association analyses.
Remaining cases were considered unclassifiable.
Statistics
We estimated crude 1-year prevalence with 95 % CI for
all headache, migraine and TTH, and point prevalence
for all headache on ≥15 days/month and pMOH. We
adjusted prevalences for gender and age according to
the general population distribution (within the range
18–65 years) in Nepal [20].
We categorized age in five groups (18–25, 26–35,
36–45, 46–55 and 56–65 years). We classed habita-
tion as rural or urban, and categorized altitude of the
household as <500 m, 500–999 m, 1,000–1,499 m,
1,500–1,999 m, 2,000-2,499 m or ≥2,500 m. We took
household consumption per year in USD (at the time
of the survey, USD 1 = NPR 100) as an indicator of
the economic wellbeing of the participant and catego-
rized it in three groups: poorest (<USD 950/year);
poor (USD 950–1,200/year); intermediate and above
(>USD 1,200/year).
We used bivariate and multivariate logistic regression
analyses (with odds ratios [ORs] and adjusted ORs
[AORs] respectively, each with 95 % CIs) to investigate
associations of demographic, lifestyle, environmental and
other health factors with each of migraine, TTH and
pMOH. Gender, age, household consumption, habitation,
altitude, systolic and diastolic BP and EPQRS-N and
HADS scores were entered as covariates in the multivari-
ate logistic regression. BP readings and EPQRS-N and
HADS scores were treated as continuous variables.
Statistical analyses were carried out using the Statistical
Package for Social Science software (IBM SPSS Statistics
21, Chicago, USA).
Results
The survey was completed by 2,100 participants (1,239
[59.0 %] female, 861 [41.0 %] male) aged 18–65 years
(mean age 36.4 ± 12.8 years). There were only nine re-
fusals: hence the participation rate was 99.6 %. Almost
two-fifths (822; 39.1 %) were living in households with
the poorest economic wellbeing; nearly two thirds
(1,328; 63.2 %) were from rural areas; over half (1,100;
52.4 %) were resident above 1,000 m and almost one
quarter (470; 22.4 %) lived at or above 2,000 m. The
sociodemographic characteristics of the sample are
compared with those of the national population (as
far as they are available) from the 2011 population
and housing census [20] in Table 1.
Headache prevalences
All headache
Of the 2,100 participants, 1,794 reported headache in
the last year. The crude 1-year prevalence of all head-
ache was 85.4 % (95 % CI: 83.9-86.9 %), higher in
females (89.2 %) than in males (80.0 %; p < 0.001). The
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gender- and age-adjusted 1-year prevalence was 84.9 %.
The age-adjusted female-to-male ratio was 1.1.
Migraine
The crude 1-year prevalence of migraine was 34.7 %
(17.5 % definite, 17.2 % probable). Prevalence was age-
related, increasing from young adulthood (18–25 years)
in both genders and peaking during 26–35 years among
males and 36–45 years among females (Fig. 1).
There was a clear female preponderance (overall
38.2 % versus 28.9 % in males) (Table 2), which is dem-
onstrated in Fig. 1 in all age groups except 26–35 years
and was confirmed in both bivariate (OR = 1.6 [95 % CI:
1.3–1.9]; p <0.001) (Table 3) and multivariate regression
analysis (AOR = 1.5 [95 % CI: 1.2-1.8]; p < 0.001)
(Table 4). The gender- and age-adjusted 1-year preva-
lence was 34.1 % and the age-adjusted female-to-male
ratio was 1.3.
Tension-type headache
The crude 1-year prevalence of TTH was 41.1 % (32.5 %
definite, 8.6 % probable). Prevalence was lower in fe-
males (38.7 %) than in males (44.6 %; OR = 0.7 [95 % CI:
0.6–0.9]; p = 0.002) (Tables 2, 3). The gender- and age-
adjusted prevalence was 41.5 % and the age-adjusted
female-to-male ratio was 0.86. Prevalence was highest in
the age range 18–25 years and decreased with age in both
genders, being at its lowest at 56–65 years (OR = 0.6 [95 %
CI: 0.4–0.8]; p < 0.001) (Table 3). Multivariate regression
analysis (Table 4) confirmed that TTH was negatively
associated with female gender (AOR = 0.7 [95 % CI:
0.6–0.9]; p = 0.003) and age (for age 56–65 years,
AOR = 0.6 [95 % CI: 0.4–0.9]; p = 0.008).
Headache on ≥15 days/month and pMOH
The crude prevalence of all headache on ≥15 days/month
was 7.7 % (95 % CI: 6.6-8.8 %), higher in females (9.4 %)
than males (5.1 %; p < 0.001). The age-adjusted female-to-
male ratio was 1.86. The gender- and age-adjusted preva-
lence was 7.4 %.
Over one quarter (46/161; 28.6 %) of the participants
reporting headache on ≥15 days/month fulfilled our cri-
teria for pMOH. The crude prevalence of pMOH was
therefore 2.2 % (95 % CI: 1.6-2.8). This disorder was
much more common in females (2.8 %) than males
(1.3 %; OR = 2.2 [95 % CI: 1.1–4.4]; p = 0.020; AOR = 2.6
[95 % CI: 1.2–5.3]; p = 0.010). The age-adjusted female-
to-male ratio was 2.42 (Tables 2, 3, 4). Prevalence in-
creased with age and was highest in the age range 56–65
years (OR = 3.7 [95 % CI: 1.2–11.4]; p = 0.023) (Table 3).
The gender- and age-adjusted prevalence was 2.1 %.
The most commonly overused acute treatment was
paracetamol in monotherapy (26 cases [56.5 %]). In 6
cases (16.1 %), there was overuse of herbal medicines,
usually navaratna sancho and zandubalm, which are cus-
tomarily inhaled or administered via the nasal mucosa
for treatment of headache in Nepal.
Associations with household consumption, habitation,
and household altitude
None of the headache disorders was associated with
household consumption (Table 4). TTH was weakly
associated with urban dwelling (OR = 1.4 [95 % CI:
Table 1 Sociodemographic characteristics of the participating
sample (N = 2,100) and national population
Variable Sample National population [20]
n (%) %
Gender
Male 861 (41.0) 46.6
Female 1,239 (59.0) 53.4
Age (years)
18–25 489 (23.3) 27.7
26–35 657 (31.3) 26.1
36–45 438 (20.8) 20.4
46–55 298 (14.2) 14.8
56-65 218 (10.4) 11.0
Household consumption
(USD/year)
<950 822 (39.1) Data not available
950–1200 806 (38.4)
>1,200 472 (22.5)
Habitation
Rural 1,328 (63.2) 72.8
Urban 772 (36.8) 27.2
Household altitude
<1,000 m 1,000 (47.6) Data not available
≥1,000 m 1,100 (52.4)
Fig. 1 1-year prevalence of migraine by age and gender
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Table 2 Observed 1-year prevalence (% [95 % CI]) of all headache and headache types by gender, age, household consumption,
habitation and altitude
All headache Migraine Tension-type headache All headache on ≥15 days/month Probable medication-overuse headache
Gender
Male 80.0 [77.2–82.6] 28.9 [25.9–31.9] 44.6 [41.3–47.9] 5.1 [3.6–6.6] 1.3 [0.5–2.1]
Female 89.2 [87.3–90.8] 38.2 [35.5–40.9] 38.7 [36.0–41.4] 9.4 [7.8–11.0] 2.8 [1.9–3.7]
Age (years)
18–25 87.1 [83.7–89.9] 31.3 [27.2–35.4] 48.3 [43.9–52.7] 5.9 [3.8–8.0] 1.0 [0.1–1.9]
26–35 88.4 [85.8–90.7] 36.7 [33.0–40.4] 40.6 [36.8–44.4] 7.8 [5.8–9.8] 2.7 [1.5–3.9]
36–45 81.7 [77.7–85.2] 36.1 [31.6–40.6] 36.8 [32.3–41.3] 7.8 [5.3–10.3] 1.6 [0.4–2.8]
46–55 86.6 [82.1–90.1] 33.9 [28.5–39.3] 41.9 [36.3–47.5] 9.7 [6.3–13.1] 2.6 [0.8–4.4]
56–65 78.4 [72.3–83.6] 34.4 [28.1–40.7] 33.9 [27.6–40.2] 8.3 [4.6–12.0] 3.7 [1.2–6.2]
Household consumption (USD/year)
950–1,200 85.2 [82.6–87.6] 34.4 [31.1–37.7] 41.4 [38.0–44.8] 7.3 [5.5–9.1] 2.2 [1.2–3.2]
<950 83.5 [80.7–85.9] 35.2 [31.9–38.5] 39.2 [35.9–42.2] 7.2 [5.4–9.0] 1.5 [0.7–2.3]
>1,200 89.2 [85.9–91.7] 34.3 [30.0–38.6] 43.9 [39.4–48.4] 9.1 [6.5–11.7] 3.4 [1.8–5.0]
Habitation
Rural 83.4 [81.3–85.4] 35.2 [32.6–37.7] 38.0 [35.4–40.6] 8.1 [6.6–9.6] 2.0 [1.3–2.7]
Urban 88.9 [86.4–90.9] 33.8 [30.5–37.1] 46.5 [43.0–50.0] 7.0 [5.1–8.8] 2.6 [1.5–3.7]
Household altitude
<1,000 m 84.5 [82.3–86.7] 28.7 [25.9–31.5] 46.4 [43.3–49.5] 8.2 [6.5–9.9] 1.8 [1.0–2.6]
≥1,000 m 86.3 [84.3–88.3] 40.1 [37.2–43.0] 36.3 [33.5–39.1] 9.7 [7.9–11.4] 2.5 [1.6–3.4]
Table 3 Bivariate logistic regression analyses of associations of each headache type with gender, age, household consumption,
habitation and altitude
Migraine Tension-type headache Probable medication-overuse headache
OR [95 % CI] p OR [95 % CI] p OR [95 % CI] p
Gender
Male Reference – Reference – Reference –
Female 1.6 [1.3–1.9] <0.001 0.7 [0.6–0.9] 0.002 2.2 [1.1–4.4] 0.020
Age (years)
18–25 Reference – Reference – Reference –
26–35 1.3 [0.99–1.6] 0.057 0.7 [0.6–0.9] 0.010 2.7 [1.01–7.4] 0.049
36–45 1.2 [0.9–1.6] 0.12 0.6 [0.5–0.8] <0.001 1.6 [0.5–4.9] 0.44
46–55 1.1 [0.8–1.5] 0.45 0.8 [0.6–1.1] 0.085 2.7 [0.9–8.2] 0.088
56–65 1.1 [0.8–1.6] 0.41 0.6 [0.4–0.8] <0.001 3.7 [1.2–11.4] 0.023
Household consumption (USD/year)
950–1,200 Reference – Reference – Reference –
<950 1.1 [0.8–1.3] 0.74 0.9 [0.7–1.1] 0.35 0.6 [0.3–1.4] 0.25
>1,200 0.99 [0.8–1.3] 0.99 1.1 [0.9–1.4] 0.40 1.5 [0.8–3.0] 0.22
Habitation
Rural Reference – Reference – Reference –
Urban 0.9 [0.8–1.1] 0.53 1.4 [1.2–1.7] <0.001 1.3 [0.7–2.4] 0.34
Household altitude
<1,000 m Reference – Reference – Reference –
≥1,000 m 1.7 [1.4–2.0] <0.001 0.7 [0.6–0.8] <0.001 1.4 [0.8–2.6] 0.25
OR odds ratio, CI confidence interval
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1.2–1.7]; p = 0.001; AOR = 1.3 [95 % CI: 1.1-1.6]; p =
0.003) (Tables 3 and 4). Migraine was strongly associ-
ated with living at an altitude of ≥1,000 m in both
bivariate (OR = 1.7 [95 % CI: 1.4-2.0]; p < 0.001)
(Table 3) and multivariate analyses (AOR = 1.6 [95 %
CI: 1.3–2.0]; p < 0.001) (Table 4). In view of this find-
ing, we estimated the prevalence of migraine by alti-
tude category, standardising for age and gender
against census data for the Nepali population [20]
(Table 5). This analysis revealed that the age- and
gender standardised prevalence of migraine was
27.9 % in the low-lying Terai (<500 m; there were no
participants in our sample living between 500 and
999 m). Prevalence increased in an almost linear rela-
tionship with altitude up to 2,000 m. Thereafter it
levelled, and indeed declined. This relationship was
evident in both genders.
A negative association between TTH and altitude was
indicated by both bivariate (OR = 0.7 [95 % CI: 0.6–0.8];
p < 0.001) and multivariate analyses (AOR = 0.7 [95 %
CI: 0.6–0.8]; p < 0.001) (Tables 3 and 4).
Discussion
We found a gender- and age adjusted 1-year prevalence
of all headache of 84.9 %, of migraine 34.1 %, of TTH
41.5 %, of all headache on ≥15 days/month 7.4 %, and of
pMOH 2.1 %. We showed that living at an altitude of
≥1,000 m was highly associated with migraine, and
urban dwelling was less strongly associated with TTH.
Before discussing the individual headache types, we
note that our study used tried and tested methods [21].
We randomly selected from the whole of Nepal, while
the very high participation rate (>99 %) achieved
through careful methodology [10, 15] effectively ex-
cluded participation bias. Face-to-face interviews were
conducted carefully to ensure there were no missing
data. These were considerable strengths of the study.
There were, however, some important limitations, which
we will draw attention to in the context of their
relevance.
Prevalence of migraine
Our most obvious finding was that the prevalence of
migraine in Nepal is very much higher than the mean
global estimate of 14.7 % [22]. Our first comment on
this is to note that more recent studies, in all regions
except the Far East, have generally yielded higher
values than 14.7 %. The mean global estimate is
based on a large number of heterogeneous studies,
performed with varying methods during a period of
>30 years. Many reports are silent on the crucial
issue of how they applied diagnostic criteria with
Table 4 Multivariate logistic regression analyses of associations of each headache typea
Migraine Tension–type headache Probable medication–overuse headache
AOR [95 % CI] p AOR [95 % CI] p AOR [95 % CI] p
Gender
Male Reference – Reference – Reference –
Female 1.5 [1.2–1.8] <0.001 0.7 [0.6–0.9] 0.003 2.6 [1.2–5.3] 0.010
Age (years)
18–25 Reference – Reference – Reference –
26–35 1.3 [1.0–1.6] 0.060 0.8 [0.6–0.9] 0.023 2.7 [0.9–7.5] 0.054
36–45 1.2 [0.9–1.6] 0.19 0.7 [0.5–0.8] 0.004 1.5 [0.5–4.8] 0.52
46–55 1.1 [0.8–1.4] 0.75 0.9 [0.7–1.2] 0.44 2.1 [0.7–6.8] 0.21
56–65 1.1 [0.8–1.6] 0.57 0.6 [0.4–0.9] 0.008 2.6 [0.8–8.8] 0.11
Household consumption (USD/year)
950–1,200 Reference – Reference – Reference –
<950 1.0 [0.8–1.2] 0.94 1.0 [0.8–1.2] 0.76 0.6 [0.3–1.2] 0.16
>1,200 1.1 [0.8–1.4] 0.66 1.1 [0.8–1.2] 0.58 1.3 [0.7–2.4] 0.44
Habitation
Rural Reference – Reference – Reference –
Urban 1.0 [0.8–1.2] 0.81 1.3 [1.1–1.6] 0.003 1.3 [0.7–2.4] 0.44
Household altitude
<1,000 m Reference – Reference – Reference –
≥1,000 m 1.6 [1.3–2.0] <0.001 0.7 [0.6–0.8] <0.001 1.4 [0.8–2.6] 0.29
aAdjusted for gender, age, household consumption, household altitude, systolic and diastolic blood pressure, EPQRS–N and HADS scores; AOR adjusted odds ratio,
CI confidence interval
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respect to definite and probable migraine; while some
explicitly excluded the latter, it is highly probable that
more did so without making this evident, because
only recently has there been clear guidance and ex-
planation of why this is misleading [21]. The conse-
quences, in our view, are that many of these studies
significantly underestimate migraine prevalence and,
therefore, so does the global mean. Nonetheless, our
finding of 34.1 % in Nepal is considerably higher even
than the 25.2 % reported from neighbouring India [23]
(although this was from the single State of Karnataka in
the south). We used the same methodology and diag-
nostic questionnaire as Karnataka [24]; indeed, LTB has
supported studies using similar methods and the same
questionnaire in many other countries, cultures and lan-
guages [13]: in Russia [25], China [26], Zambia [27],
Ethiopia (unpublished), Pakistan (unpublished), Saudi
Arabia (unpublished), Morocco (unpublished). None
has discovered such a high prevalence of migraine; in
fact, India (Karnataka) was the highest [23].
Nepal is a poor country, but we discovered no associ-
ation with economic wellbeing that might offer an ex-
planation (neither was there one in India [23]). The
clearly relevant factor is altitude: over half our sample
were resident at or above 1,000 m, and nearly one
quarter above 2,000 m. Altitude, we discovered, is an en-
vironmental factor so strongly associated with migraine
that living above 1,000 m led to 60 % increased odds of
having the disorder. In practice this meant that, among
the adult population living above this altitude, an
additional 11.4 % had migraine (Table 2). Since more
than half the population were in fact living above
1,000 m, this explained a very large part of the overall
excess prevalence. For the remainder, we should look
to the distinctive age and gender distributions of
Nepal: more precisely, to the high proportions of
young adults (median age is 22 years [9]), and females
among these adults, the two strongest determinants
of migraine prevalence [1]. Furthermore, large num-
bers of healthy people have consistently been going
abroad for work, around half of them in the age
group 15–35 years, and mostly males [9], leaving be-
hind a skewed adult distribution perhaps more at risk
of migraine. It is entirely possible to see this as the
explanation of the difference between 27.9 %, the
standardised prevalence in the Terai of Nepal, and
25.2 %, the standardised prevalence in Karnataka [23]
(which is at a mean altitude of about 900 m [28]).
We should acknowledge two diagnostic issues. First,
it was a limitation of the study that we were not able
to perform a prior validation of the headache diag-
nostic questionnaire in its Nepali translation. Because
there are no headache specialists in the country, we
had no means of applying a “gold standard” for this
purpose [21]. We had to rely on the fact that the
questionnaire had been validated in many other lan-
guages and countries [13], including India with not
too dissimilar cultural settings [24].
Second, having said this, we encountered a problem
that was not met in India: such a large proportion
(75.8 %) of respondents with any type of headache re-
ported photophobia that this symptom had virtually no
discriminative value as a diagnostic criterion, and we
could not use it within the framework of ICHD [18].
Photophobia is a technical concept, not easy to convey
to lay participants (even by trained interviewers) [21].
Because of this we had taken great care in translation to
convey not merely an aversion to bright light but the
idea of a wish to withdraw into darkness from ordinary
light. Our eventual solution was to disregard photopho-
bia altogether, and in our view this was necessary: the
prevalence estimate for migraine would otherwise have
been much higher. What this suggests is that ICHD
criteria – or at least this particular one – may not be
universally applicable, and not for linguistic reasons.
Other headache types
The estimated prevalence of TTH in Nepal at 41.1 % is in
line with the estimated global average [2], although con-
siderably lower than some national estimates [29, 30].
Table 5 Observed and age- and gender-standardised prevalence of migraine by altitude and gender
Physiographic
division and altitude
Observed prevalence in sample Standardised prevalence* [20]
N All n (%) Male n (%) Female n (%) All % Male % Female %
Terai <500 m 1,000 287 (28.7) 86 (22.0) 201 (33.0) 27.9 22.1 32.9
Hill
1,000–1,499 m 470 176 (37.7) 57 (31.1) 119 (41.5) 36.5 31.6 40.7
1,500–1,999 m 160 68 (42.5) 31 (39.7) 37 (45.1) 44.4 41.3 47.0
Mountain
2,000–2,499 m 254 116 (45.7) 46 (41.1) 70 (49.3) 45.5 40.8 49.6
≥2,500 m 216 81 (37.5) 29 (29.9) 52 (43.7) 37.9 31.4 43.6
*Age- and gender-standardised against census data for the Nepali population [20]
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Two factors are relevant here. One is whether or not sur-
vey participants report infrequent TTH, which can have a
marked effect on the prevalence estimate and is likely to
be determined in part culturally and in part by the insist-
ence (and purpose) of the interviewer [23, 24]. In our case,
not only did we not consider infrequent TTH to be of
public-health significance, but also we focused only on the
most bothersome headache in participants identifying
more than one type. Those with both migraine and
TTH would tend to regard the former as the more
bothersome [31], leading to a partial neglect of TTH.
Our prevalence estimate for TTH was therefore
somewhat conservative.
We suspect this was a factor in the observed nega-
tive association between TTH prevalence and altitude:
as migraine prevalence increased with altitude, report-
ing of TTH became less likely. In other words, it was
artefactual. We do not know this, but on the other
hand can offer no explanation for a true negative
association.
TTH was significantly more prevalent in urban areas,
an association not observed for migraine or pMOH. Pos-
sible explanations for the higher prevalence of TTH may
be the noisy and stressful environments of the cities.
Also, physical inactivity is a risk factor specifically for
non-migraine headache [32], and people in rural areas in
Nepal are more physically active working in the fields.
These are speculative proposals.
According to our estimate, the prevalence of headache
on ≥15 days/month in Nepal is more than twice the
global average [2] and much higher than in neighbouring
China [26] and India [23]. Several factors such as low
socio-economic status, poor access to health services
with a paucity of health-care providers and lack of
standard protocols for diagnosis and treatment of head-
ache disorders, all against a background of high levels of
episodic headache, offer what may be sufficient
explanation.
We do not know what the cases with headache on
≥15 days/month were diagnostically, other than the pro-
portion diagnosed as pMOH. We estimated the preva-
lence of pMOH in Nepal at 2.1 %, which is towards
the upper end of the range for most countries studied
(0.5–2.6 %) [33], and much higher than the 0.6 % and
1.2 % in neighbouring China [26] and India [23]. Sur-
prisingly, the proportion of pMOH among those with
headache on ≥15 days/month was only 29 % (46/161);
in other countries where studies have used similar
methodology, this proportion is closer to two thirds
[23, 25, 26]. This may be due to poverty: most pMOH
was associated with overuse of simple analgesics sold
over-the-counter (OTC), but many people in Nepal can-
not afford these. They have recourse to alternative treat-
ments, which may include plant-based remedies that are
used regularly across the country, especially in the rural
areas. Many of these have phytochemical or pharma-
cological properties [34], and may be able to cause
transformation of episodic headache to pMOH. We
endeavoured to include these in our enquiry, and identi-
fied six cases, but herb-based remedies may not be per-
ceived by lay people as therapy for headache and it is
likely that they were underreported.
Implications for Nepal
Headache disorders are very common in Nepal. Only
the prevalence of TTH is in line with the global average.
That of headache on ≥15 days/month is double, while
the prevalence of pMOH is towards the upper end of
the range for most countries studied. The prevalence of
migraine, however, appears uniquely high, explained, we
believe, by some of the distinct characteristics of this
country. One is the combination of mountainous and
hilly terrain over much of the country, important in the
light of the previously unreported but strong association
between migraine prevalence and altitude. Another is
the demographic make-up.
The new evidence from this study will inform national
health policy, and provide a basis for health-care needs
assessment. Meanwhile, research of a different type is
needed to find explanations for the association between
migraine and altitude, since these may be relevant to
health-care interventions. Continuous long-duration ex-
posure to high altitude compromises oxygen uptake and
results in haemodynamic changes, with elevated haemo-
globin levels, increased blood viscosity and reduced
oxygen delivery to brain tissues [35, 36]. Migraine has
been linked with the consequences of such changes
[37–40], but their relevance at lower altitudes, be-
tween 500 and 2,000 m, needs to be investigated.
Conclusion
Headache disorders are very common in Nepal. Migraine
is unusually so, and strongly associated with altitude of
dwelling, which in this mountainous country largely ex-
plains the high national prevalence. Headache occurring
on ≥15 days/month is also very common in comparison
with the world average. This new evidence will inform na-
tional health policy and provide a basis for health-care
needs assessment. However, research is needed to explain
the association of migraine with altitude, since it may be
relevant to health-care interventions.
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